WelcomeLatest News: Immune Design welcomes Dr. Carl June to the Scientific Advisory BoardImmune Design Corp. (IDC) is a privately held biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world’s leaders in the field of molecular immunology to develop therapeutic vaccines for the treatment of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms. The first technology is a novel synthetic toll-like receptor 4 (TLR-4) agonist known as GLA, which is a clinical stage adjuvant being utilized in multiple internal and partnered vaccine programs. The second technology is a novel viral vector (DC-NILV), which has been engineered to target immature dendritic cells, expressing target antigens together with select immunomodulatory elements to enhance the potency of the induced cellular immune response. DC-NILV is significantly more potent than competing recombinant vectors while overcoming the inherent limitations of these other platforms, and is initially being advanced to the clinical in cancer indications of significant unmet need. The most significant innovations on human health have occurred through the directed manipulation of the immune system. Vaccines that stimulate durable immunity protect against viral and bacterial pathogens, and immunotherapeutics show great promise in treating chronic infections and malignant disease. Recent advances in molecular immunology have led to new approaches to vaccine design and development and have created new and important ways to treat infectious disease and cancer. IDC is using this knowledge to discover and develop therapeutics that will protect and save lives world-wide. |